Holen Sie sich die Stockscreener-App
0.562
7.81%
-0.0476
Schlusskurs vom Vortag:
$0.6096
Offen:
$0.5804
24-Stunden-Volumen:
223.38K
Relative Volume:
0.04
Marktkapitalisierung:
$2.04M
Einnahmen:
$5.07M
Nettoeinkommen (Verlust:
$-10.18M
KGV:
-0.1332
EPS:
-4.2178
Netto-Cashflow:
$-7.93M
1W Leistung:
+9.34%
1M Leistung:
+2.72%
6M Leistung:
-76.87%
1J Leistung:
-75.46%
1-Tages-Spanne:
$0.5344
$0.5826
1-Wochen-Bereich:
$0.489
$0.61
52-Wochen-Spanne:
$0.3144
$4.85
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Firmenname
Ensysce Biosciences Inc
Sektor
Branche
Telefon
(858) 263-4196
Adresse
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.562 | 2.21M | 5.07M | -10.18M | -7.93M | -4.2178 |
VRTX
Vertex Pharmaceuticals Inc
|
433.53 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.09 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.56 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.57 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ensysce Biosciences Inc Aktie (ENSC) Neueste Nachrichten
Ensysce Biosciences, Inc. Announces Director Resignation in April 2026 Form 8-K Filing - Minichart
Ensysce Biosciences director Curtis Rosebraugh resigns from board - Investing.com
Ensysce Biosciences Announces Board Member Curtis Rosebraugh Resignation - TipRanks
Board member Curtis Rosebraugh exits Ensysce Biosciences (NASDAQ: ENSC) - Stock Titan
ENSC SEC FilingsEnsysce Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ENSC Stock Price, Quote & Chart | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce Biosciences, Inc. — Business Overview, Risk Factors, Regulatory Approvals, and Intellectual Property Challenges 64 - Minichart
8-K: Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - bitget.com
Smart Money: Will Ensysce Biosciences Inc benefit from geopolitical trendsWeekly Market Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Ensysce Biosciences (NASDAQ: ENSC) outlines abuse-resistant opioid pipeline - Stock Titan
ENSC: Net loss widened to $10.2 million in 2025; ongoing operations depend on new capital raises - TradingView
Ensysce Biosciences Reports Q4 and Full Year 2025 Results - National Today
Ensysce (NASDAQ: ENSC) advances PF614 programs as 2025 net loss hits $10.2M - Stock Titan
Ensysce Biosciences Q4 net loss narrows to $2.8 mln - TradingView
Ensysce pushes abuse-deterrent opioid into late-stage testing - Stock Titan
Ensysce Biosciences (NASDAQ: ENSC) director quits after opposing retention deals - stocktitan.net
Revenue Check: Does Ensysce Biosciences Inc meet Warren Buffetts criteria2026 Highlights & Low Risk High Reward Ideas - baoquankhu1.vn
Weekly Trades: Is Ensysce Biosciences Inc a turnaround story2026 Snapshot & Fast Exit and Entry Trade Guides - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Ensysce Biosciences Files Certificate of Correction for Series B Preferred Stock with Delaware Secretary of State - Minichart
Ensysce Biosciences files correction to Series B preferred stock designation By Investing.com - Investing.com South Africa
Ensysce Biosciences Corrects Series B Preferred Stock Designation - TipRanks
Ensysce Biosciences files correction to Series B preferred stock designation - Investing.com
Ensysce Biosciences (ENSC) files correction to Series B preferred stock - Stock Titan
If You Invested $1,000 in Ensysce Biosciences Inc (ENSC) - Stock Titan
ENSC Should I Buy - Intellectia AI
Earnings Recap: Is Travere Therapeutics Inc stock heavily shorted2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Risk Analysis: Is Ensysce Biosciences Inc being accumulated by smart money2026 Setups & Daily Profit Focused Screening - baoquankhu1.vn
Ensysce Biosciences Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
ENSC Earnings History & Surprises | EPS & Revenue Results | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Market Fear: Will Ensysce Biosciences Inc benefit from geopolitical trendsJuly 2025 Setups & Smart Swing Trading Alerts - baoquankhu1.vn
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Pl - PharmiWeb.com
CEO takes live questions on Ensysce PF614 pain-drug plans - Stock Titan
Ensysce publishes phase 1 data on overdose-limiting opioid tech By Investing.com - Investing.com Australia
ENSC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
Ensysce publishes phase 1 data on overdose-limiting opioid tech - Investing.com India
New opioid design limits drug release when too many pills are swallowed - Stock Titan
Promising Penny Stocks To Add to Your Watchlist – March 1st - Defense World
Dow Dips Over 600 Points; US Producer Prices Increase In January - Sahm
Top Penny Stocks To Follow TodayFebruary 27th - MarketBeat
Ensysce Biosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Ensysce Biosciences (ENSC) over sub-$1 minimum bid price - Stock Titan
Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Benzinga
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - Corsicana Daily Sun
Opioid safety drug developer Ensysce explores deals, possible asset sales - Stock Titan
Market Overview: Is Ensysce Biosciences Inc subject to activist investor interest2025 Market Outlook & Weekly Watchlist of Top Performers - baoquankhu1.vn
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events - Corsicana Daily Sun
Finanzdaten der Ensysce Biosciences Inc-Aktie (ENSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):